Press Release: Novartis announces FDA approval of -2-

security and data privacy breaches, or disruptions of our information

technology systems, and other risks and factors referred to in Novartis

AG's current Form 20-F on file with the US Securities and Exchange

Commission. Novartis is providing the information in this press release

as of this date and does not undertake any obligation to update any

forward-looking statements contained in this press release as a result

of new information, future events or otherwise.

About Novartis

Novartis provides innovative healthcare solutions that address the

evolving needs of patients and societies. Headquartered in Basel,

Switzerland, Novartis offers a diversified portfolio to best meet these

needs: innovative medicines, cost-saving generic and biosimilar

pharmaceuticals and eye care. Novartis has leading positions globally in

each of these areas. In 2017, the Group achieved net sales of USD 49.1

billion, while R&D throughout the Group amounted to approximately USD

9.0 billion. Novartis Group companies employ approximately 124,000

full-time-equivalent associates. Novartis products are sold in

approximately 155 countries around the world. For more information,

please visit http://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at

http://twitter.com/novartis

For Novartis multimedia content, please visit

www.novartis.com/news/media-library

For questions about the site or required registration, please contact

media.relations@novartis.com

References

[1] National Multiple Sclerosis Society. Pediatric MS.

http://www.nationalmssociety.org/What-is-MS/Who-Gets-

MS/Pediatric-MS. Accessed April 2018.

[2] Gilenya(R) (fingolimod) Full Prescribing Information. East

Hanover, New Jersey, USA: Novartis Pharmaceuticals Corporation; May 11,

2018

[3] Novartis Pharmaceuticals. Data on file.

[4] Chitnis T et al. PARADIGMS: A Randomised Double-blind Study of

Fingolimod Versus Interferon ß-1a in Paediatric Multiple Sclerosis.

Abstract no. 276. Oral presentation at 7(th) Joint ECTRIMS-ACTRIMS

Meeting, Paris, France, October 25-28, 2017.

[5] Clinical Trials. Safety and efficacy of fingolimod in pediatric

patients with multiple sclerosis.

https://clinicaltrials.gov/ct2/show/NCT01892722. Accessed April 2018.

[6] PubMed Health. Multiple Sclerosis (MS).

https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0024311/. Accessed April

2018.

[7] Multiple Sclerosis Society. Types of MS.

https://www.mssociety.org.uk/what-is-ms/types-of-ms. Accessed April

2018.

[8] Multiple Sclerosis International Federation. Atlas of MS 2013.

https://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf.

Accessed April 2018.

[9] Waldman A et al. Pediatric multiple sclerosis: Clinical features

and outcome. Neurol. 2016; 87(Suppl 2):S74-S81.

[10] Tullman M. Overview of the epidemiology, diagnosis and disease

progression associated with multiple sclerosis. Am J Managed Care. 2013

Feb;19(2 Suppl):S15-20.

# # #

Novartis Media Relations

Central media line: +41 61 324 2200

E-mail: media.relations@novartis.com

Eric Althoff Angela Fiorin

Novartis Global Media Relations Novartis Global Pharma Communications

+41 61 324 7999 (direct) +41 61 324 8631 (direct)

+41 79 593 4202 (mobile) +41 79 752 6955 (mobile)

eric.althoff@novartis.com angela.fiorin@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448

Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 830 2417

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

Media release (PDF) : http://hugin.info/134323/R/2192142/848713.pdf

This announcement is distributed by Nasdaq Corporate Solutions on behalf

of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely

responsible for the content, accuracy and originality of the information

contained therein.

Source: Novartis International AG via Globenewswire

--- End of Message ---

Novartis International AG

P.O. Box Basel Switzerland

WKN: 904278;ISIN: CH0012005267;

http://www.novartis.com

(END) Dow Jones Newswires

May 11, 2018 18:24 ET (22:24 GMT)